chronic%20obstructive%20pulmonary%20disease
CHRONIC OBSTRUCTIVE PULMONARY DISEASE

Chronic obstructive pulmonary disease (COPD) is an inflammatory respiratory disease characterized by reversible airflow limitation.

The patient usually have chronic cough, sputum production or dyspnea with or without history of risk factors for the disease.

The chronic airflow limitation is caused by a combination of small airways disease and parenchymal destruction.

It is a preventable & treatable disease.

Supportive Therapy

O2 Therapy 
Long-term Management

  • Long-term administration of O2 (>15 hours/day) increases survival in patients with chronic respiratory failure
    • O2 therapy may also benefit hemodynamics, hematologic characteristics, exercise capacity, lung mechanics & mental state
  • Given to patients with stage IV (very severe) COPD with the following:
    • PaO2 ≤55 mmHg (7.3 kPa) or SaO2 ≤88% with or without hypercapnia confirmed 2x over a 3-week period or
    • PaO2 between 55-60 mmHg (7.3-8 kPa) or SaO2 88%, if there is evidence of pulmonary hypertension, peripheral edema suggesting congestive heart failure, or polycythemia
  • Aim is to increase baseline PaO2 to ≥60 mmHg (8 kPa) &/or produce SaO2 ≥90%, thus preserving vital organ function
  • Inappropriate use of O2 therapy may result in respiratory depression
  • Patients must be given adequate instructions about the source of O2 to be used, method of delivery, duration of use, & flow rates to be used for different levels of physical activity (eg at rest, during exercise, during sleep)
  • Patients should be warned to discontinue smoking when prescribed O2

Hospital Management

  • Cornerstone of hospital treatment for COPD exacerbations & in patients with chronic respiratory failure
  • Goal of O2 therapy is to maintain SaO2 >90% without precipitating respiratory acidosis or worsening hypercapnia
  • SaO2 >93% is not advisable as patient may become drowsy from CO2 retention
  • Once O2 is started, ABG must be checked after 30-60 minutes to ensure adequate oxygenation without CO2 retention or acidosis
    • Blood gases must be monitored regularly depending on response to treatment

Hydration & Nutrition

  • Fluid balance & nutritional status must be monitored & maintained at an optimal level

Mechanical Ventilation
Non-invasive Mechanical Ventilation (NIV)

  • First-line treatment of acute hypercapnic respiratory failure in COPD exacerbation in patients without contraindications
  • Usually employed in patients with ≥1 of the following: severe dyspnea with signs of respiratory muscle fatigue, &/or increased work of breathing (eg use of accessory muscles, intercostal space retraction), acidosis (pH <7.35 &/or PaCO>6.0 kPa, 45 mmHg), persistent hypoxemia despite supplemental O2 therapy
  • Has been shown to increase pH, reduce PaCO2, reduce severity of breathlessness in the 1st 4 hours of treatment & decrease length of hospital stay, mortality & intubation rate

Invasive Mechanical Ventilation

  • Utilized in patients with the following:
    • With contraindications to non-invasive mechanical ventilation or failed non-invasive mechanical ventilation 
    • Life-threatening hypoxemia unresponsive to NIV 
    • Severe dyspnea
    • Impending respiratory or cardiac failure
    • Apnea with loss of consciousness
    • Gasping for air
    • Altered mental status in spite of aggressive pharmacotherapy
    • Severe hemodynamic compromise unresponsive to hydration & medications
    • Massive aspiration
    • Unable to suction resp secretions
    • <50 bpm PR with loss of consciousness
    • Severe ventricular arrhythmias
    • Psychomotor agitation unresponsive to sedatives
  • There is a major risk of ventilator-associated pneumonia, barotrauma & failure to wean
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Respirology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
Pearl Toh, 19 Jun 2016
Infants with persistent rhinitis have a higher abundance of Actinobacteria, especially Corynebacterium spp., in their nasal microbiome compared with healthy controls, according to a Singapore-based study presented at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress 2016 held in Vienna, Austria.
29 Nov 2017
Lansoprazole, a widely available and commonly prescribed proton pump inhibitor (PPI), appears to reduce the incidence of tuberculosis disease, a recent study has found.
Gabriel Angelo Sembrano, 16 Sep 2014

“At present, there is a limited development of new antibiotics. There is also a fast development of resistance to antibiotics. There are pathogens no longer susceptible to all antibiotics, and many pathogens are no longer susceptible to most antibiotics,” said Dr. Andre Villanueva, chief of party of the USAID’s Innovations and Multisectoral Partnerships to Achieve Control of TB (IMPACT) Project at the recent Annual Convention of the Philippine Pharmacists’ Association in Davao City.

Pearl Toh, 31 May 2016
Synbiotic mixture of oligosaccharides and Bifidobacterium breve (B. breve) M-16V probiotic strain in infant formula restores gut colonisation by B. breve and supports healthy gut development in infants delivered by Caesarean-section (C-section), according to a study presented at the recent European Society for Paediatric Gastroenterology Hepatology and Nutrition (ESPGHAN) annual meeting held in Athens, Greece.